Dr Fuh, welcome to the Medscape InDiscussion: Endometrial Cancer ... molecular testing is IHC. With mismatch repair protein, IHC is also ER, PR, then, in some places, HER2 IHC.

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

ImmunityBio has announced the launch of the Phase I/II QUILT 502 clinical trial of ANKTIVA (nogapendekin alfa inbakicept-pmln), plus the investigational AdHER2DC vaccine, as a potential therapy ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.